Applied DNA Sciences Files 8-K with Bylaw Amendments

TL;DR

APDN filed an 8-K on 4/22/24 for bylaw changes and financial updates.

AI Summary

Applied DNA Sciences, Inc. filed an 8-K on April 22, 2024, reporting amendments to its Articles of Incorporation or Bylaws, a Regulation FD Disclosure, and financial statements/exhibits. The company, incorporated in Delaware with its fiscal year ending September 30, is located at 50 Health Sciences Drive, Stony Brook, NY.

Why It Matters

This filing indicates potential changes in the company's governance or operational structure, which could impact its strategic direction and shareholder rights.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of corporate actions and financial information, not indicating immediate operational or financial distress.

Key Numbers

• 001-36745 — SEC File Number (Identifies the company's filing history with the SEC.)
• 59-2262718 — IRS Number (Company's Employer Identification Number.)

Key Players & Entities

• Applied DNA Sciences, Inc. (company) — Registrant
• Delaware (jurisdiction) — State of incorporation
• April 22, 2024 (date) — Date of earliest event reported
• 50 Health Sciences Drive, Stony Brook, NY (location) — Business address

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value APDN The Nasdaq Stock Mar

Filing Documents

• tm2412346d1_8k.htm (8-K) — 34KB
• tm2412346d1_ex3-1.htm (EX-3.1) — 6KB
• tm2412346d1_ex99-1.htm (EX-99.1) — 10KB
• image_001.jpg (GRAPHIC) — 7KB
• 0001104659-24-050056.txt ( ) — 238KB
• apdn-20240422.xsd (EX-101.SCH) — 3KB
• apdn-20240422_lab.xml (EX-101.LAB) — 33KB
• apdn-20240422_pre.xml (EX-101.PRE) — 22KB
• tm2412346d1_8k_htm.xml (XML) — 4KB

01

Item 7.01. Regulation FD Disclosure. On April 22, 2024, the Company issued a press release announcing the Reverse Stock Split. A copy of the press release is attached as Exhibit 99.1 hereto. The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation forward-looking statements reflect the Company's beliefs and assumptions only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to update forward-looking statements to reflect future events or circumstances. Capitalized terms shall have the meanings ascribed to such terms in the Current Report on Form 8-K.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 3.1 Form of Sixth Certificate of Amendment to the Certificate of Incorporation 99.1 Press Release, dated April 22, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 22, 2024 APPLIED DNA SCIENCES, INC. By: /s/ James A. Hayward Name: James A. Hayward Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR